혈액암 치료제 시장 조사 보고서(2026년)

The global Blood Cancer Drugs market was valued at US$ 74605 million in 2025 and is anticipated to reach US$ 138811 million by 2032, at a CAGR of 9.21% from 2026 to 2032.

The North American market for Blood Cancer Drugs is projected to increase from US$ 36621 million in 2025 to US$ 62671 million by 2032, at a CAGR of 7.79% over 2026-2032.

The Asia-Pacific market for Blood Cancer Drugs is projected to rise from US$ 18666 million in 2025 to US$ 41952 million by 2032, at a CAGR of 12.35% over 2026-2032.

Major global companies of Blood Cancer Drugs include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately 49.54% of revenue.

This report delivers a comprehensive overview of the global Blood Cancer Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Drugs. The Blood Cancer Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021-2032.

The report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes by Type, by Disease, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Blood Cancer Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Disease, and by region.

Market Segmentation

By Company

• Johnson & Johnson
• Bristol-Myers Squibb
• Novartis
• AbbVie
• Roche
• BeiGene
• Amgen
• AstraZeneca
• Incyte Corporation
• Takeda
• Gilead Sciences
• Pfizer
• Sanofi
• Astellas Pharma

Segment by Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Other

Segment by Disease

• Leukemia
• Lymphoma
• Multiple Myeloma

Segment by Region

• North America
  • U.S.
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Rest of Europe
• South America
  • Brazil
• Middle East & Africa
  • Middle East
  • Africa

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Disease, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Blood Cancer Drugs companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Disease, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 6-10: Regional deep dives (North America, Europe, Asia Pacific, South America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
  • 1.2.2 Chemotherapy
  • 1.2.3 Targeted Therapy
  • 1.2.4 Immunotherapy
• 1.3 Market by Disease
  • 1.3.1 Global Blood Cancer Drugs Market Growth by Disease: 2021 vs 2025 vs 2032
  • 1.3.2 Leukemia
  • 1.3.3 Lymphoma
  • 1.3.4 Multiple Myeloma
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Blood Cancer Drugs Market Perspective (2021-2032)
• 2.2 Global Blood Cancer Drugs Growth Trends by Region
  • 2.2.1 Global Blood Cancer Drugs Market Size by Region: 2021 vs 2025 vs 2032
  • 2.2.2 Blood Cancer Drugs Historic Market Size by Region (2021-2026)
  • 2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2027-2032)
• 2.3 Blood Cancer Drugs Market Dynamics
  • 2.3.1 Blood Cancer Drugs Industry Trends
  • 2.3.2 Blood Cancer Drugs Market Drivers
  • 2.3.3 Blood Cancer Drugs Market Challenges
  • 2.3.4 Blood Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Blood Cancer Drugs Players by Revenue
  • 3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2021-2026)
  • 3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2021-2026)
• 3.2 Global Top Blood Cancer Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
• 3.3 Global Key Players Ranking by Blood Cancer Drugs Revenue
• 3.4 Global Blood Cancer Drugs Market Concentration Ratio
  • 3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2025
• 3.5 Global Key Players of Blood Cancer Drugs Head Offices and Areas Served
• 3.6 Global Key Players of Blood Cancer Drugs, Products
• 3.7 Global Key Players of Blood Cancer Drugs, Founded Date
• 3.8 Mergers and Acquisitions, Expansion Plans

4 Blood Cancer Drugs Breakdown Data by Type

• 4.1 Global Blood Cancer Drugs Historic Market Size by Type (2021-2026)
• 4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2027-2032)

5 Blood Cancer Drugs Breakdown Data by Disease

• 5.1 Global Blood Cancer Drugs Historic Market Size by Disease (2021-2026)
• 5.2 Global Blood Cancer Drugs Forecasted Market Size by Disease (2027-2032)

6 North America

• 6.1 North America Blood Cancer Drugs Market Size (2021-2032)
• 6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
• 6.3 North America Blood Cancer Drugs Market Size by Country (2021-2026)
• 6.4 North America Blood Cancer Drugs Market Size by Country (2027-2032)
• 6.5 United States
• 6.6 Canada
• 6.7 Mexico

7 Europe

• 7.1 Europe Blood Cancer Drugs Market Size (2021-2032)
• 7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
• 7.3 Europe Blood Cancer Drugs Market Size by Country (2021-2026)
• 7.4 Europe Blood Cancer Drugs Market Size by Country (2027-2032)
• 7.5 Germany
• 7.6 France
• 7.7 U.K.
• 7.8 Italy
• 7.9 Russia

8 Asia-Pacific

• 8.1 Asia-Pacific Blood Cancer Drugs Market Size (2021-2032)
• 8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
• 8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2021-2026)
• 8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2027-2032)
• 8.5 China
• 8.6 Japan
• 8.7 South Korea
• 8.8 Southeast Asia
• 8.9 India

9 South America

• 9.1 South America Blood Cancer Drugs Market Size (2021-2032)
• 9.2 South America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
• 9.3 South America Blood Cancer Drugs Market Size by Country (2021-2026)
• 9.4 South America Blood Cancer Drugs Market Size by Country (2027-2032)
• 9.5 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Blood Cancer Drugs Market Size (2021-2032)
• 10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
• 10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2021-2026)
• 10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2027-2032)
• 10.5 Middle East
• 10.6 Africa

11 Key Players Profiles

• 11.1 Bristol-Myers Squibb
  • 11.1.1 Bristol-Myers Squibb Company Details
  • 11.1.2 Bristol-Myers Squibb Business Overview
  • 11.1.3 Bristol-Myers Squibb Blood Cancer Drugs Introduction
  • 11.1.4 Bristol-Myers Squibb Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.1.5 Bristol-Myers Squibb Recent Development
• 11.2 Johnson & Johnson
  • 11.2.1 Johnson & Johnson Company Details
  • 11.2.2 Johnson & Johnson Business Overview
  • 11.2.3 Johnson & Johnson Blood Cancer Drugs Introduction
  • 11.2.4 Johnson & Johnson Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.2.5 Johnson & Johnson Recent Development
• 11.3 AbbVie
  • 11.3.1 AbbVie Company Details
  • 11.3.2 AbbVie Business Overview
  • 11.3.3 AbbVie Blood Cancer Drugs Introduction
  • 11.3.4 AbbVie Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.3.5 AbbVie Recent Development
• 11.4 Novartis
  • 11.4.1 Novartis Company Details
  • 11.4.2 Novartis Business Overview
  • 11.4.3 Novartis Blood Cancer Drugs Introduction
  • 11.4.4 Novartis Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.4.5 Novartis Recent Development
• 11.5 Roche
  • 11.5.1 Roche Company Details
  • 11.5.2 Roche Business Overview
  • 11.5.3 Roche Blood Cancer Drugs Introduction
  • 11.5.4 Roche Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.5.5 Roche Recent Development
• 11.6 Amgen
  • 11.6.1 Amgen Company Details
  • 11.6.2 Amgen Business Overview
  • 11.6.3 Amgen Blood Cancer Drugs Introduction
  • 11.6.4 Amgen Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.6.5 Amgen Recent Development
• 11.7 Takeda
  • 11.7.1 Takeda Company Details
  • 11.7.2 Takeda Business Overview
  • 11.7.3 Takeda Blood Cancer Drugs Introduction
  • 11.7.4 Takeda Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.7.5 Takeda Recent Development
• 11.8 Pfizer
  • 11.8.1 Pfizer Company Details
  • 11.8.2 Pfizer Business Overview
  • 11.8.3 Pfizer Blood Cancer Drugs Introduction
  • 11.8.4 Pfizer Revenue in Blood Cancer Drugs Business (2021-2026)
• 11.9 AstraZeneca
  • 11.9.1 AstraZeneca Company Details
  • 11.9.2 AstraZeneca Business Overview
  • 11.9.3 AstraZeneca Blood Cancer Drugs Introduction
  • 11.9.4 AstraZeneca Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.9.5 AstraZeneca Recent Development
• 11.10 Gilead Sciences
  • 11.10.1 Gilead Sciences Company Details
  • 11.10.2 Gilead Sciences Business Overview
  • 11.10.3 Gilead Sciences Blood Cancer Drugs Introduction
  • 11.10.4 Gilead Sciences Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.10.5 Gilead Sciences Recent Development
• 11.11 Sanofi
  • 11.11.1 Sanofi Company Details
  • 11.11.2 Sanofi Business Overview
  • 11.11.3 Sanofi Blood Cancer Drugs Introduction
  • 11.11.4 Sanofi Revenue in Blood Cancer Drugs Business (2021-2026)
• 11.12 Incyte Corporation
  • 11.12.1 Incyte Corporation Company Details
  • 11.12.2 Incyte Corporation Business Overview
  • 11.12.3 Incyte Corporation Blood Cancer Drugs Introduction
  • 11.12.4 Incyte Corporation Revenue in Blood Cancer Drugs Business (2021-2026)
• 11.13 BeiGene
  • 11.13.1 BeiGene Company Details
  • 11.13.2 BeiGene Business Overview
  • 11.13.3 BeiGene Blood Cancer Drugs Introduction
  • 11.13.4 BeiGene Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.13.5 BeiGene Recent Development
• 11.14 Astellas Pharma
  • 11.14.1 Astellas Pharma Company Details
  • 11.14.2 Astellas Pharma Business Overview
  • 11.14.3 Astellas Pharma Blood Cancer Drugs Introduction
  • 11.14.4 Astellas Pharma Revenue in Blood Cancer Drugs Business (2021-2026)
  • 11.14.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer